Celltrion Inc
KRX:068270
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
If you don’t study any companies, you have the same success buying stocks as you do in a poker game if you bet without looking at your cards.
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
151 800
198 229.0871
|
| Price Target |
|
We'll email you a reminder when the closing price reaches KRW.
Choose the stock you wish to monitor with a price alert.
|
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
|
Bank of America Corp
NYSE:BAC
|
US |
|
|
Mastercard Inc
NYSE:MA
|
US |
|
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
|
Pfizer Inc
NYSE:PFE
|
US |
|
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
|
Nike Inc
NYSE:NKE
|
US |
|
|
Visa Inc
NYSE:V
|
US |
|
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
|
Coca-Cola Co
NYSE:KO
|
US |
|
|
Walmart Inc
NYSE:WMT
|
US |
|
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Celltrion Inc
Celltrion Inc
Revenue
Celltrion Inc
Revenue Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Revenue | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Celltrion Inc
KRX:068270
|
Revenue
₩3.6T
|
CAGR 3-Years
23%
|
CAGR 5-Years
26%
|
CAGR 10-Years
22%
|
|
|
SK Bioscience Co Ltd
KRX:302440
|
Revenue
₩267.5B
|
CAGR 3-Years
-34%
|
CAGR 5-Years
8%
|
CAGR 10-Years
N/A
|
|
|
H
|
Hugel Inc
KOSDAQ:145020
|
Revenue
₩373B
|
CAGR 3-Years
17%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
P
|
PharmaResearch Co Ltd
KOSDAQ:214450
|
Revenue
₩350.1B
|
CAGR 3-Years
31%
|
CAGR 5-Years
33%
|
CAGR 10-Years
30%
|
|
|
Alteogen Inc
KOSDAQ:196170
|
Revenue
₩102.9B
|
CAGR 3-Years
38%
|
CAGR 5-Years
29%
|
CAGR 10-Years
31%
|
|
|
A
|
ABL Bio Inc
KOSDAQ:298380
|
Revenue
₩33.4B
|
CAGR 3-Years
84%
|
CAGR 5-Years
53%
|
CAGR 10-Years
N/A
|
|
Celltrion Inc
Glance View
Celltrion Inc. stands as a significant player in the global biopharmaceutical industry, rooted in the heart of South Korea's bustling innovation scene. Founded in 2002 by Seo Jung-Jin, the company initially carved its niche in the development of biosimilars, which are near-identical versions of original biological drugs whose patents have expired. With rapid advancements in biotechnology, Celltrion has well-positioned itself to tap into the expanding market for affordable and accessible biologic treatments. At the core of its operation is its cutting-edge production facilities equipped with high-tech fermentation and purification processes necessary for manufacturing these complex medicines. This foundational expertise has allowed Celltrion to pioneer some of the world's first monoclonal antibody biosimilars, including those for autoimmune diseases and oncological conditions, thereby cementing its reputation as a forerunner in global biosimilar development. The company’s revenue model is intricately tied to its production capabilities and strategic partnerships. By leveraging its advanced manufacturing infrastructure, Celltrion not only produces its own line of biosimilars but also collaborates with global pharmaceutical companies to license and distribute its products worldwide. Such partnerships have enabled Celltrion to penetrate markets across Europe, the Americas, and Asia, with its biosimilars gaining regulatory approval in many regions. Furthermore, Celltrion’s business is not limited to biosimilars; it is actively investing in novel biologics and innovative delivery systems. This diversification strategy underscores its commitment to sustainable growth and reducing dependence on any single product line, ultimately fostering a robust pipeline that promises to meet the healthcare industry's evolving demands.
See Also
What is Celltrion Inc's Revenue?
Revenue
3.6T
KRW
Based on the financial report for Dec 31, 2024, Celltrion Inc's Revenue amounts to 3.6T KRW.
What is Celltrion Inc's Revenue growth rate?
Revenue CAGR 10Y
22%
Over the last year, the Revenue growth was 63%. The average annual Revenue growth rates for Celltrion Inc have been 23% over the past three years , 26% over the past five years , and 22% over the past ten years .
You don't have any saved screeners yet